Heart failure medical device developer BioVentrix(BVXX.US) applies for IPO in the US, planning to raise $17 million

LootboxPhobia · 2026-02-13T23:07:40+00:00

Medical device company BioVentrix files for IPO with the SEC, planning to raise up to $17 million, focusing on treating heart failure with reduced ejection fraction using the Revivent system. The device employs minimally invasive surgical technology and is expected to replace traditional heart surgery.

LootboxPhobia

2026-02-13 23:07:40

Abstract generation in progress

Bloomberg News has learned that medical device company BioVentrix (BVXX.US), which focuses on developing minimally invasive heart failure treatment technologies, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, aiming to raise up to $17 million through an initial public offering (IPO).

BioVentrix is a medical device company that develops and commercializes treatments for heart failure with reduced ejection fraction (HFrEF). Its core product, the Revivent system, is designed to restore left ventricular function in HFrEF patients with anterior wall scarring caused by previous myocardial infarction. The device uses titanium alloy anchors connected by PEEK sutures, and is implanted through minimally invasive small incisions, folding scarred, non-functional myocardial tissue and reducing left ventricular volume. The procedure is performed while the heart is still beating, offering a less invasive alternative to traditional open-heart surgeries such as ventricular assist device implantation and heart transplants. Previously, BioVentrix generated revenue through sales of the Revivent TC® transcatheter ventricular enhancement system, which was discontinued in 2023 to conserve funds.

Headquartered in Mansfield, Massachusetts, the company was founded in 2003 and plans to list on the Nasdaq under the ticker symbol BVXX. BioVentrix filed a confidential registration statement on August 5, 2025. The IPO is underwritten exclusively by The Benchmark Company, and the offering price has not yet been disclosed.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.